High Expression of <i>NTRK1</i> in <i>ETV6::RUNX1</i> Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib

NTRK1 overexpression has not previously been reported in B-ALL and was associated with increased relapse in patients with ETV6::RUNX1 and NTKR1 overexpression. The in vitro success of larotrectinib treatment warrants further in vivo investigation and may be a viable therapeutic addition for patients with ETV6::RUNX1 B-ALL and NTRK1 overexpression.